ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3152

The IL-21 Signaling Pathway Is Enhanced in RA B Cells and Has the Potential to Alter Development and Cytokine Production in RA B Cells

Jane H. Buckner1 and Elizabeth Samuelson2, 1Benaroya Research Institute at Virginia Mason, Seattle, WA, 2Translational Research, Benaroya Research Institute at Virginia Mason, Seattle, WA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: B cells, cytokines and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: B cell Biology and Targets in Autoimmune Disease: Novel B cell roles in RA and SLE

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: B cells have been implicated in the development of rheumatoid arthritis (RA) based on their production of autoantibodies and cytokines as well as the therapeutic response to B cell depletion therapy. The maturation of B cells occurs in the germinal center and is influenced by multiple factors including T cell dependent CD40-CD40L signals, toll-like receptor signals and cytokines including BAFF and IL-21. Each of these is a potential therapeutic target in RA. In this study we examined the response to IL-21 as measured by phosphorylation of STAT3 (pSTAT3), to better understand its potential role in RA.

Methods: We utilized frozen PBMC from a cohort of RA subjects and healthy controls obtained from the BRI Rheumatic disease Registry. Samples were thawed, rested for 1 hour and were stimulated with cytokine; IL-21 (50 ng/mL and 15 pg/mL) for 15 and 45 minutes (n=20 per group); IL-10 for 10 min at 10 ng/mL (n=20 per group); or IL-4 at 100 ng/mL for 15 min (RA n=10, Control n=12).  Response to IL-21 and IL-10 was measured as mean fold change in phosphorylation of STAT3 (pSTAT3) and for IL-4 pSTAT6. IL-21R, the common gamma chain and total STAT3 expression were determined through flow cytometric analysis.

Results: We determined that RA subjects exhibit enhanced IL-21 signaling in total B cells (p = 0.02), memory B cells (p = 0.0096), IgM+ memory B cells (0.01), naïve B cells (p = 0.02) and transitional B cells (0.005) but not in the more mature switched memory B cells as compared to controls. We observed no significant differences in IL-10 or IL-4 stimulations. Further, IL-21 signaling in total B cells of RA subjects as measured by pSTAT3 positively correlated with the expression of IL-21R (p = 0.0004, r = 0.70). Similarly we found a significant correlation with the common gamma chain level of expression (p = 0.01, r = 0.55). When we measured total STAT3 we observed no significant differences between RA and control subjects.

Conclusion: We found that the response to IL-21 is enhanced in the B cells of subjects with RA in comparison to healthy age and gender matched controls.  This is unique to IL-21 and not other cytokines; IL-4 which signal through the common gamma chain nor IL-10 which signaling via STAT3, suggesting a link with the IL-21R specifically. Consistent with this we found an increase in the expression of the IL-21R on the cell surface. This heightened response has the potential to enhance or alter the maturation of B cells leading to alterations in antibody and cytokine production in RA. Characterizing the response to IL-21 in RA B cells is important as it relates to disease pathogenesis but also is vital as therapeutics that target this cytokine and its signaling pathway are currently under development. Thus this work may have implications with respect to how best to use such drugs in the setting of RA.


Disclosure: J. H. Buckner, None; E. Samuelson, None.

To cite this abstract in AMA style:

Buckner JH, Samuelson E. The IL-21 Signaling Pathway Is Enhanced in RA B Cells and Has the Potential to Alter Development and Cytokine Production in RA B Cells [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/the-il-21-signaling-pathway-is-enhanced-in-ra-b-cells-and-has-the-potential-to-alter-development-and-cytokine-production-in-ra-b-cells/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-il-21-signaling-pathway-is-enhanced-in-ra-b-cells-and-has-the-potential-to-alter-development-and-cytokine-production-in-ra-b-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology